# Abnormal Uterine Bleeding (AUB)

## Normal Menstrual Bleeding

- **Frequency:** Every **24–38 days**
- **Duration:** **≤8 days**
- **Volume:** Average **30–40 mL**, but up to **80 mL** is normal
- **Cycle variability:** ≤7–9 days

## Heavy Menstrual Bleeding (HMB)

- **Excessive menstrual blood loss** that:

  - **Interferes with physical, emotional, social or material quality of life**
  - Objectively: **>80 mL per cycle** (though rarely measured)

## Types of Abnormal Uterine Bleeding (AUB)

> Based on **PALM-COEIN system** (FIGO Classification)

### A. Structural Causes (PALM)

| Type                           | Pathology                                     |
| ------------------------------ | --------------------------------------------- |
| **P** – Polyp                  | Endometrial or cervical                       |
| **A** – Adenomyosis            | Endometrial tissue in myometrium              |
| **L** – Leiomyoma (fibroids)   | Submucosal or other types                     |
| **M** – Malignancy/Hyperplasia | Endometrial carcinoma or atypical hyperplasia |

### B. Non-Structural Causes (COEIN)

| Type                          | Pathology                                                 |
| ----------------------------- | --------------------------------------------------------- |
| **C** – Coagulopathy          | e.g., von Willebrand disease                              |
| **O** – Ovulatory dysfunction | PCOS, hypothyroidism, obesity, adolescence, perimenopause |
| **E** – Endometrial           | Primary endometrial dysfunction                           |
| **I** – Iatrogenic            | Anticoagulants, IUCD, hormones                            |
| **N** – Not yet classified    | Rare or undefined disorders                               |

## Causes of Heavy Menstrual Bleeding (HMB)

### A. Structural

- **Submucosal fibroids (Leiomyoma)**
- **Endometrial/cervical polyps**
- **Adenomyosis**
- **Endometrial hyperplasia or cancer**

### B. Hormonal / Functional

- **Anovulation** (PCOS, perimenopause, thyroid disorders)
- **Endometrial dysfunction**
- **Coagulopathy** (e.g., von Willebrand disease)
- **Iatrogenic** (hormones, IUCD, anticoagulants)

### C. Others

- Chronic pelvic infection
- Endometriosis
- Liver/kidney failure (affecting coagulation)

## Diagnosis of Heavy Menstrual Bleeding

### A. Symptoms

- Soaking through sanitary products every 1–2 hours
- Passing large clots
- Need for double protection (pad + tampon)
- Menstrual flow >7 days
- Fatigue, dizziness (anemia)

### B. Signs

- **Pallor** (from anemia)
- **Uterine enlargement** (fibroids)
- **Tender boggy uterus** (adenomyosis)
- **Pelvic mass**
- **Speculum exam:** polyps, cervical lesion
- **Bimanual exam:** size, mobility of uterus

### C. Investigations

#### 1. For Diagnosis

- **CBC**: Detect anemia
- **Pelvic ultrasound (TVS preferred)**: Uterine pathology: fibroid, polyp, endometrial thickness
- **Endometrial biopsy** (if >45 yrs or risk factors): Rule out hyperplasia or malignancy
- **High Vaginal Swab (if discharge)**: Infection
- **TSH, Prolactin**: Rule out hypothyroid, hyperprolactinemia
- **Pregnancy test**: Always exclude early pregnancy complications

#### 2. For Causes

- **Coagulation profile, vWF assay** : In young or lifelong HMB suspicion
- **LFT/RFT** : Chronic illness
- **Hysteroscopy** : Direct visualization of cavity: polyp, submucosal fibroid

## Management

> **Reduce menstrual blood loss**<br/>Correct anemia<br/>Improve quality of life

### I. Initial Assessment

- Exclude **pregnancy**
- Identify **underlying cause** using **PALM-COEIN classification**
- Assess **severity**, impact on life, and **woman’s preference** (fertility desire, uterine preservation)

---

### II. Management Overview

| Category                 | Approach                                                                    |
| ------------------------ | --------------------------------------------------------------------------- |
| **Medical (First-line)** | If no structural abnormality or mild/moderate fibroids                      |
| **Surgical**             | If medical fails or pathology is significant (e.g., large fibroids, polyps) |

### III. Medical Treatment

#### Indication

- No significant structural lesion or ≤3 cm fibroids not distorting cavity
- Desire to **preserve fertility or avoid surgery**

#### 1. First-line: Levonorgestrel Intrauterine System (LNG-IUS)

e.g., `Mirena®`

- Releases progestogen locally → suppresses endometrium
- Reduces bleeding by **>90% in 6 months**

**Advantages:**

- Long-term (up to 5 years)
- Contraceptive
- Minimal systemic effects

**Contraindications:**

- Distorted uterine cavity
- Active pelvic infection
- Suspicion of malignancy

#### 2. Antifibrinolytics: Tranexamic Acid

- **Mechanism:** Inhibits plasminogen activation → stabilizes clot
- Dose: **500–1000 mg TDS** during menstruation (max 5 days/cycle)

**Advantages:**

- Non-hormonal
- Useful in women desiring pregnancy
- ↓ Blood loss by \~40–60%

**Side effects:** Nausea, risk of thrombosis (caution in VTE history)

#### 3. NSAIDs: Mefenamic Acid / Ibuprofen

- **Mechanism:** ↓ Prostaglandins → reduces uterine contraction and blood flow
- Dose: `Mefenamic acid 500 mg` TDS during menstruation

**Benefits:**

- ↓ Blood loss by \~30%
- Relieves dysmenorrhoea

**Caution:** GI irritation, asthma, renal impairment

#### 4. Combined Oral Contraceptive Pills (COCP)

- **Mechanism:** Cyclic estrogen + progestin → endometrial thinning, cycle regulation
- Dose: e.g., **Ethinylestradiol 30–35 mcg + progestin**, 21/7 cycle

**Advantages:**

- Regulates cycle
- Contraceptive
- Improves acne, PMS

**Contraindications:** Smoking + age >35, migraine with aura, VTE risk

#### 5. Oral Progestins

Used in two ways:

- **Cyclically (days 5–26)**: e.g., `Norethisterone 5 mg TDS`
- **Continuously**: for anovulatory cycles

**Effectiveness:** Less than LNG-IUS, better for anovulatory bleeding

**Side effects:** Bloating, mood swings, weight gain

#### 6. GnRH Agonists (e.g., `Leuprolide`, `Goserelin`)

- **Mechanism:** Suppress pituitary → ↓ estrogen → amenorrhoea
- Indicated in **severe bleeding with fibroids** or **preoperative shrinkage**

**Limitation:**

- Use limited to **≤6 months** due to **bone loss**, menopausal symptoms
- Add-back HRT often needed

### IV. Non-Medical Support

- **Iron supplementation** for anemia
- **Counseling** on menstrual charting
- Treat underlying **hypothyroidism**, **bleeding disorders**

### V. Surgical Options

- If medical therapy fails or contraindicated

| Procedure                                  | Indication                                    |
| ------------------------------------------ | --------------------------------------------- |
| **Endometrial ablation**                   | Completed family, small uterus, no malignancy |
| **Myomectomy**                             | Fibroids with fertility desire                |
| **Hysteroscopic polypectomy / myomectomy** | Polyps / submucosal fibroids                  |
| **Hysterectomy**                           | Definitive if failed all other options        |

---

### Summary: Medical Management by Priority

| Drug                | Best Use                                 | Blood Loss ↓ |
| ------------------- | ---------------------------------------- | ------------ |
| **LNG-IUS**         | Long-term, uterine preservation          | **\~90%**    |
| **Tranexamic acid** | Heavy regular periods, fertility desired | 40–60%       |
| **NSAIDs**          | Pain + bleeding                          | \~30%        |
| **COCP**            | Cycle control + contraception            | 40–50%       |
| **Oral progestins** | Anovulatory bleeding, short-term         | Variable     |
| **GnRH agonists**   | Large fibroids, short-term pre-op        | Marked ↓     |
